CARA VS NVS Stock Comparison
Performance
CARA10/100
10/100
CARA returned -89.02% in the last 12 months. Based on SPY's performance of -20.58%, its performance is below average giving it a score of 10 of 100.
NVS100/100
100/100
NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
CARA79/100
79/100
7 analysts offer 12-month price targets for CARA. Together, they have an average target of 28, the most optimistic target put CARA at 30 within 12-months and the most pessimistic has CARA at 26.
NVS67/100
67/100
3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.
Sentiment
CARA67/100
67/100
CARA had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 7.42 posts, 3.60 comments, and 9.03 likes per day.
NVS
"Sentiment" not found for NVS
Technicals
CARA14/100
14/100
CARA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
NVS10/100
10/100
NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
CARA10/100
10/100
CARA has missed earnings 6 times in the last 20 quarters.
NVS39/100
39/100
NVS has missed earnings 5 times in the last 20 quarters.
Profit
CARA10/100
10/100
Out of the last 20 quarters, CARA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
NVS73/100
73/100
Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
CARA41/100
41/100
CARA has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
NVS44/100
44/100
NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Cara Therapeutics, Inc. Summary
Nasdaq / CARA
Healthcare
Biotechnology
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Novartis AG Summary
New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CARA to other companies in the same or a similar industry.